Note: Descriptions are shown in the official language in which they were submitted.
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
1
MARKER GENES FOR USE IN THE IDENTIFICATION OF CHONDROCYTE
PHENOTYPIC STABILITY AND IN THE SCREENING OF FACTORS
INFLUENCING CARTILAGE PRODUCTION
FIELD OF THE INVENTION
The present invention relates to methods and tools for determining
chondrocyte phenotypic stability and screening systems for identifying
compounds of use in the treatment of cartilage defects and cartilage related
diseases.
BACKGROUND
Repair of cartilage defects is mainly achieved by surgical methods such
as bone marrow stimulation techniques or by the implantation of cartilage
forming cells (chondrocytes, (chondro-) progenitors and precursors thereof or
stem cells which develop into cartilage). In view of this, the identification
of
factors capable of positively affecting in vivo cartilage formation is of
interest. It
is indeed desirable to identify surgical procedures, or therapeutic methods or
compounds capable of positively affecting cartilage formation mediated by
local
cells present in or in the vicinity of the defect. In addition, it is of
interest for cell-
based therapies to identify factors or treatments which can positively affect
the
ability of isolated cell populations that have been expanded or passaged in
vitro
to produce stable cartilage in vivo.
Different assays have been described wherein the expression of genes
involved in cartilage formation is used as a parameter for screening
compounds. US2002061514 describes a method wherein a reporter gene is
responsive to the transcription factor SOX9. SOX9 is a high-mobility-group
(HMG) domain transcription factor that is expressed in chondrocytes, chondro-
progenitors and other tissues and has been found to be essential for
chondrocyte differentiation and cartilage formation. Other methods are based
on the expression levels of individual genes which are involved in cartilage
metabolism and osteochondral defects [e.g. osteoporosis related genes in
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
2
W002081745].
Screening methods have also been described which are based on the in
vitro differentiation of cells into cartilage. However, the predictive value
of such
models has been found to be limited and these assays require large amounts of
cells and are time consuming.
W0200466723 provides an in vivo model wherein the effect of
compounds on bone and cartilage formation in zebrafish is evaluated in vivo.
One of the most reliable models for assessing the ability of cells to form
stable
cartilage is the intramuscular implantation of cells into nude mice followed
by
the histological evaluation of the generated implants. The use of this nude
mouse model, which in itself is time-consuming and impractical for high-
throughput screening, was avoided with the technology disclosed in
W00124833. This patent application describes the use of molecular markers,
identified based on the nude mouse model for cartilage formation, to evaluate
the chondrogenic potential of expanded or passaged cells for transplantation
purposes. Similarly, a set of suitable markers for chondrocyte phenotypic
stability are described in US2003235813. However, while the identification of
these markers provided a basis for the identification of cell populations
capable
of producing stable hyaline cartilage in vivo, there remains a need for
further
improvement.
SUMMARY OF THE INVENTION
The present invention is based on the novel concept of providing a
specific marker profile which is indicative of cartilage formation in any
given
circumstance, i.e. whether native to the cells or induced, which can be
considered as the target profile in the identification of factors capable of
affecting cartilage formation.
Accordingly, the present invention provides a set of markers, which can
be reliably used to predict the cartilage forming potential of a population of
cells.
The expression level of these markers can be used to predict whether a cell
population, e.g. in vitro or in vivo, is able to produce cartilage in vivo
upon
implantation or upon stimulation. This is of interest for determining the
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
3
therapeutic potential of a cell population. The set of markers also provides a
reliable tool to determine the impact of a given treatment on the chondrocyte
phenotypic stability of a population of cells prior to implantation.
Furthermore
the present invention provides for combined treatment regimes comprising the
administration of stem cells or osteochondral cells in a joint and the
administration of a medicament affecting the chondrogenic potential of the
administered cell population.
According to the present invention, the phenotypic stability of a cell
population in vitro is used in screening assays for the identification of
factors
capable of affecting chondrocyte phenotypic stability in vitro and/or in vivo.
The
invention provides a set of markers indicative of chondrocyte phenotypic
stability, the expression of which is used to predict the effect in vitro or
in vivo of
compounds and/or conditions on the ability of a cell population to produce
cartilage in vivo. The use of these markers in screening assay allows the
screening of a large number of compounds and/or conditions on chondrocytes,
without performing time consuming and laborious animal experiments.
In one aspect of the invention methods for determining the ability of a cell
population to produce stable hyaline cartilage are provided. More
particularly,
methods are provided for determining in vitro the ability of a cell population
to
produce stable hyaline cartilage in vivo. In particular embodiments, methods
are
provided which comprise determining the expression by the cell population of a
set of at least three marker genes comprising FRZB, ALK1 and one or more
markers selected from the group consisting of PEDF, COL11, COL2, FGFR3,
OPN, BMP-2 and RASF-PLA.
In particular embodiments of methods provided herein, the cell
population is contacted with a compound or condition.
In particular embodiments, methods are provided which comprise the
steps of contacting a population of cells with a compound or condition, and
determining the expression level in the population of cells of a set of at
least
three marker genes comprising FRZB, ALK1 and one or more marker genes
selected from the group consisting of PEDF, COL11, COL2, FGFR3, OPN,
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
4
BMP-2 and RASF-PLA. In these methods, the expression level of the set of at
least three markers is indicative of the ability of the cells to produce
stable
hyaline cartilage in vivo, e.g. upon implantation into a patient.
Further embodiments of methods described herein comprise the steps
of, prior to contacting the cell population with a compound or condition,
determining in the population of cells the expression level of the set of at
least
three marker genes, and, after the contacting step, determining whether the
the
presence of the compound or condition affects the expression in the cell
population of one or more of the set of at least three marker genes. More
particularly, methods are provided which comprise determining, based on the
effect of the presence of the compound or condition on the expression of the
set
of at least three marker genes in the cell population, the effect of the
compound
or condition on the ability of the cell population to produce stable hyaline
cartilage in vivo. In particular embodiments of the methods described herein,
compounds or conditions capable of increasing the expression of one or more
positive marker genes selected from the group consisting of FRZB, COL11,
COL2, FGFR3, OPN, BMP-2 and RASF-PLA are identified as positively
affecting cartilage formation and compounds capable of increasing the
expression of either PEDF and/or ALK-1 are identified as negatively affecting
cartilage formation, more particularly the ability of cells to produce stable
hyaline cartilage in vivo.
In further particular embodiments of methods described herein, the set of
markers are a set of at least 4, 5 or 6 marker genes comprising FRZB, ALK1
and comprising respectively 2, 3 and 4 marker genes selected from the group
consisting of PEDF, COL11, COL2, and FGFR3. More particular embodiments
of methods described herein, relate to methods wherein the of marker genes is
a set of at least six marker genes comprising FRZB, ALK1, PEDF, COL11,
COL2 and FGFR3.
In particular embodiments of methods described herein, the ability of a
compound or condition to affect cartilage formation is determined based on the
cumulative effect of the compound or condition on the expression of the set of
at least three marker genes. More particularly, the cumulative effect of the
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
compound or condition on the expression of the positive marker genes selected
from the group consisting of FRZB, COL11, COL2, FGFR3, OPN, BMP-2, and
RASF-PLA and the cumulative effect of the compound or condition on the
expression of negative marker genes PEDF and/or ALK-1 is indicative of the
5 ability of the compound or condition to affect chondrocyte phenotypic
stability of
a cell population.
In particular embodiments of methods described herein, the population of
cells is obtained from a joint. The population of cells is obtained from a
healthy
donor or from an individual with an osteochondral defect. In particular assays
the effect of a compound or condition on both types of cells is envisaged. In
particular embodiments of methods described herein the expression level of
one or more of the markers is determined with a quantitative method.
A further aspect of the invention relates to the use of a set of markers for
identifying a compound that is capable of affecting the ability of cells, more
particularly chondrocytes or chondrocyte precursor cells, to produce cartilage
in
vivo. In particular embodiments the use is characterised in that the set of
markers comprises a set of at least three marker genes comprising FRZB,
ALK1 and one or more markers selected from the group consisting of PEDF,
COL11, COL2, FGFR3, OPN, BMP-2 and RASF-PLA. In specific embodiments,
the use involves a set of at least six marker genes comprising FRZB, ALK1,
PEDF, COL11, COL2, and FGFR3.
A further aspect of the invention provides kits comprising probes for
detecting the expression of a set of genes in cartilage forming cells wherein
the
set of genes comprises a set of at least three marker genes comprising FRZB,
ALK1 and one or more markers selected from the group consisting of PEDF,
COL11, COL2, FGFR3, OPN, BMP-2 and RASF-PLA.
In specific embodiments, kits are provided wherein the set of marker
genes is a set of at least six marker genes comprising FRZB, ALK1, PEDF,
COL11, COL2, and FGFR3.
Particular embodiments of the kits provided herein are kits wherein the
CA 02670419 2014-07-28
55185-12
6
probes are oligonucleotides which hybridise with mRNA, wherein the probes are
antibodies and/or wherein the probes are sets of PCR primers specific for the
markers to be tested. Kits are envisaged which comprise different types of
probes. In further particular embodiments of the kits, labelled probes are
provided.
Yet a further aspect of the invention provides devices for detecting the
expression of a set of genes in cells, more particularly cells typically
capable of
cartilage formation. In particular embodiments of such devices, one or more of
the following components are provided: a unit for detecting the expression of
marker genes, and probes for a set of at least three marker genes comprising
FRZB, ALK1 and one or more markers selected from the group consisting of
PEDF, COL11, COL2, FGFR3, OPN, BMP-2 and RASF-PLA. Specific
embodiments of devices described herein are devices particularly suited for
detecting expression of a set of marker genes by a cell population wherein the
set of marker genes is a set of at least six marker genes comprising FRZB,
ALK1, PEDF, COL11, COL2, and FGFR3.
CA 02670419 2016-08-12
55185-12
6a
Yet a further aspect of the invention provides an in vitro method for
determining the ability of a cell population to produce stable hyaline
cartilage in vivo,
which comprises a) determining the expression by said cell population of a set
of
positive and negative marker genes expressed by cell populations capable of
producing hyaline cartilage in vivo, comprising the positive marker FRZB
(Frizzled-
Related Protein 1), the negative marker ALK1 (Activin A Receptor, Type II-Like
Kinase 1) and at least one marker selected from the group consisting of the
negative
marker PEDF (Pigment Epithelium-Derived Factor), the positive marker COL2
(Collagen, Type II, Alpha 1), and the positive marker FGFR3 (Fibroblast Growth
Factor Receptor 3), b) representing the expression level, indicative for the
ability of
cartilage formation of cells in vivo, of each individual marker by a numeric
value, c)
combining the numeric values for the individual markers into a cumulative
score
indicative for the ability of a cell population to produce phenotypically
stable cartilage
in vivo, and d) predicting, based upon the cumulative score, the ability of
said cell
population to produce stable hyaline cartilage in vivo.
Yet a further aspect of the invention provides use of a set of positive
and negative markers expressed by cell populations capable of producing
hyaline
cartilage in vivo, for identifying a compound that affects the ability of
cells to produce
cartilage formation in vitro, by combining the expression values, indicative
for the
ability cartilage formation of cells in vivo, of a set of said positive and
negative
markers into a cumulative score indicative for the ability of a cell
population to
produce phenotypically stable cartilage in vivo, comprising the positive
marker FRZB,
the negative marker ALK1 and one or more markers selected from the group
consisting of the negative marker PEDF, the positive marker COL2, and the
negative
marker FGFR3.
Yet a further aspect of the invention provides a kit comprising probes for
detecting the expression of a set of marker genes in cartilage forming cells,
said
probes consisting of probes for detecting the expression of the set of marker
genes,
CA 02670419 2016-08-12
55185-12
6b
wherein the set of marker genes consists of FRZB, ALK1, and at least one of
PEDF,
COL2 and FGFR3.
Yet a further aspect of the invention provides a device selected from the
group consisting of a PCR apparatus, a device for performing immunological
assays,
a device for determining proteins and a micro array device for detecting the
expression of a set of marker genes in cartilage forming cells, said device
comprising
the following: a unit for detecting the expression of the set of marker genes,
and
probes, said probes consisting of probes for detecting the expression of the
set of
marker genes, wherein the marker genes consist of FRZB, ALK1, PEDF, COL2 and
FGFR3.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
The term "chondrogenic" when applied to a cell or a population refers to
the inherent capacity of that cell or population to produce cartilage or to
stimulate
cartilage growth, under appropriate circumstances.
A "chondrogenic compound" as used herein refers to a compound
which induces a stable chondrocyte phenotype and/or promotes cartilage
formation.
The term "chondrocyte phenotypic stability" or "chondrogenic potential"
when referring to a cell population, refers to the ability of the cell
population to
produce cartilage in vivo. This ability can be tested by (ectopically)
injecting a
fraction of the cell population (at least about 1 ¨ 20 x 106 cells) in a
mammal (in vivo),
such as immune-deficient mice, and determining (in a time frame of about 3
weeks),
the development of a cartilage implant without signs of vascular invasion,
mineralisation or replacement by bone or fibrous tissue. Alternatively,
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
7
a fraction of the cell population (at least about 1 ¨ 20 x 106 cells per cm2)
can be
seeded onto, or encapsulated in, a biocompatible matrix and implanted
subcutaneously under the skin for about 6-8 weeks before determining the
development of a stable cartilage implant without signs of vascular invasion
or
endochondral bone formation. According to the present invention a population
of cells that is capable of producing stable hyaline cartilage in vivo, is
characterized by the presence of a specific combination of markers of
phenotypic stability described herein. Chondrocyte phenotypic stability is
gradually lost in mature chondrocytes upon passaging.
The term "freshly isolated cells" (Fl) as used herein refers to the cell
population obtained from a biopsy after tissue digestion. The term "freshly
isolated cartilage cells" as used herein thus refers to the cell population
directly
obtained from a chondrocyte-containing tissue, such as cartilage, by
digestion,
without passaging.
The term "expanded", when referring to a cell population obtained from a
tissue, such as cartilage, indicates that the cell population has been placed
under conditions whereby the number of cells has increased by proliferation.
In
its simplest version, expansion is performed by providing the cell population
in a
cultivation recipient with appropriate cultivation medium, optionally until
confluency. The population which is obtained as a result of expanding freshly
isolated cells is referred to as PO.
The term "passaged" refers to cells which have been expanded, and
which following expansion have been harvested from the cultivation recipient
using enzymatic, chemical and/or physical methods and are placed at a lower
density in another cultivation recipient. Passaged cells are referred to by
their
passage number (P1, P2, etc.) their time in culture or alternatively, by the
number of their population doublings (PD1, PD2 etc).
The term "cartilage defect" as used herein refers to any condition
resulting from the loss or damage of cartilage or any diseased portion of
cartilage.
The term "marker score" as such is used to refer to a numeric value
which can be attributed to the expression of a marker according to the present
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
8
invention. The 'cumulative marker score refers to the combination of the
marker
score of the different markers of the sets of markers of the present
invention.
This can be the result of a sum of the individual markers. Alternatively, the
cumulative marker score takes into account differences in the contribution of
each marker in the ability to predict chondrocyte phenotypic stability and
accordingly is based on a more complex mathematical formula.
The term "histology score" refers to a qualitative or semi-qualitative value
attributed to cartilage based on a histological analysis (e.g. no cartilage,
fibrocartilage, hyaline cartilage).
The abbreviations used for genes in the context of the present application
are:
FRZB: Frizzled-Related Protein 1 [OMIM 605083, Genbank U91903]
ALK1: Activin A Receptor, Type II-Like Kinase 1 [OMIM 601284,
Genbank Z225331
PEDF: Pigment Epithelium-Derived Factor [OMIM 172860, Genbank
M76979]
COL11: Collagen, Type XI A1 [OMIM 120280, Genbank J04177]
COL2: Collagen, Type II, Alpha 1 [OMIM 120140, Genbank L10347]
FGFR3: Fibroblast Growth Factor Receptor 3 [OMIM 134934, Genbank
M58051]
BMP-2: Bone Morphogenetic Protein 2 [OMIM 112261, Genbank
M22489]
RASF-PLA2: Phospholipase A2, Group IIA [OMIM 172411, Genbank
M22430]
OPN: Osteopontin [OMIM 166490, Genbank X136941
The present invention is based on the identification of a selected set of
marker genes, the expression of which has been found to be indicative for the
ability cartilage formation of cells in vivo. More specifically, it has been
determined that by attributing a value to each of these markers, the
cumulative
value, which can be expressed as a cumulative marker score, reflects the
ability
of a cell population to produce phenotypically stable cartilage in vivo.
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
9
The marker genes identified in the present invention as useful in the
assessment of the ability of a cell population to ensure cartilage formation
are
selected from the group including the positive marker genes FRZB, COL11,
COL2, FGFR3, BMP-2, RASF-PLA2, and OPN and the negative marker genes
ALK1 and PEDF. Additional markers may be included in the set, e.g. as
controls.
Thus, according to the present invention, a set of 9 markers has been
identified, comprising both positive and negative markers. Positive markers
are
strongly expressed by populations capable of producing stable hyaline
cartilage
in vivo, while negative markers are expressed at low levels or not expressed
by
populations capable of producing stable hyaline cartilage. According to the
present invention, the absence of expression of a negative marker, can serve
as a positive marker. However, in the context of the present invention such
markers of which the absence of expression is indicative of the ability of
chondrocyte phenotypic stability, are referred to herein as negative markers.
Expression of the marker genes of the present invention is a feature
characteristic of a cell population, typically consisting of around 0.2x105 -
1.0x106 cells.
Different methods for determining expression of genes are known in the
art. Most typically, according to the present invention, RNA is isolated from
a
fraction of the cell population (typically between 0.2 x105 ¨ 1.0x106 cells
and
preferably between 0.2x106 ¨ 1x106) and amplified using reverse PCR. Such
amplification can be performed in a semi-quantitative way via the
electrophoresis of amplified fragments and measurement of their relative
intensity compared with that of a housekeeping gene such as beta-actin.
However, lower amounts of cells and even individual cells can be analysed for
expression of cells using nucleotide amplification techniques. Additionally or
alternatively, the amount of DNA is measured in a quantitative way using e.g.
the Taqman technology. Primers which are suitable for the markers mentioned
in this application can easily be identified by the skilled person based on
the
known sequences of the marker genes.
Alternatively or additionally, the expression of the markers is measured
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
at the protein level. Protein levels can be determined by immunological
methods
such as Western blots or ELISA.
In specific embodiments of the invention, the expression of markers is
evaluated by comparing the expression of markers in a control population and
5 an experimental population, such as via micro array technology or
analysis after
1D or 2D protein electrophoresis. Herein, the marker proteins migrate in a gel
in
accordance with their Mr (1D) and their iso-electric point (IEP) (2D).
Differences
in expression at the protein level can be measured by detecting the amount of
protein present at the position corresponding with its Mr and/or IEP. Proteins
10 can be quantified after staining with Coomassie Brilliant Blue or an
equivalent
staining or can be quantified by incorporating a radioactive metabolic label
(eg
35S methionine).
Depending on the technology used, antibodies, oligonucleotide probes or
protein probes (such as antibodies) can be labelled, e.g. with chromophoric or
magnetic or radioactive labels, so as to allow detection of expression.
In specific embodiments it is envisaged to detect different markers by
different techniques. For example, a number of markers are detected by ELISA
while others are detected via PCR.
A further aspect of the invention provides a device suitable for the
detection of the markers of the invention. In particular embodiments such
devices comprises a unit for directly or indirectly detecting the markers of
the
present invention (at DNA, RNA, or protein level). The unit can be based on
RNA, DNA hybridization or based on immunological detection. Such a unit can
be a (quantitative) PCR apparatus, a device for performing immunological
assays, or a device for determining proteins (e.g. HPLC, mass spectrometer,
electrophoresis apparatus), but can also be a (disposable) micro array device
or
chip. Such unit is, when applicable, equipped with probes or antibodies for
detecting the marker genes or proteins of the invention. Optionally, such a
device can further comprise a cell-cultivation unit, wherein two or more cell
populations can be grown under identical or under different conditions (e.g.
density, passage number, medium composition). Furthermore the device of the
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
11
invention can comprise a unit for delivering one or more test compounds to the
cell-cultivation unit (which delivery can be individually varied in amount or
in
time-profile). Finally, the device can comprise a unit for collecting cells
and
isolating cellular material (DNA, RNA, proteins).
In addition, disposable cartridges are envisaged comprising probes or
specific reagents for the markers described herein which can be used to
determine the expression of these markers for a rapid and efficient
determination of the status of a cell population. Accordingly, the present
invention envisages automated devices, which are optionally combined with
disposable cartridges, which allow efficient quality control of cells for use
in in
vivo or in vitro applications.
According to specific embodiments of the present invention, subsets of
the marker genes identified are provided which allow a reliable assessment of
the chondrocyte phenotypic stability of a cell population or of the ability of
a
compound or condition to influence cartilage formation by a cell population in
vivo. Most particularly, suitable sets of marker genes comprise at least 3,
more
particularly at least 4, even more particularly at least 5, and most
particularly at
least 6 of the identified marker genes. According to one embodiment, a
suitable
set of marker genes comprises at least one positive marker gene and one
negative marker gene.
In general, the lower the number of marker genes taken into account, the
higher the impact of both measuring errors and the potential aberrant
expression of one particular marker. The different markers also reflect the
different processes (e.g. anabolic processes, catabolic processes, etc.) and
pathways involved in chondrocyte cell metabolism (signalling pathways,
receptors and ligands, matrix components, processing enzymes, ...) and each
of these processes can have an individual impact on chondrocyte phenotypic
stability. Thus, the more marker genes are taken into account, the more
representative the assay becomes of the complete environment ensuring stable
cartilage formation. On the other hand, the more marker genes are to be
determined, the more technically complicated the assay becomes,
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
12
compromising its ease of use in high-throughput screening. Also, in order to
maintain the relevance of the contribution of each of the marker genes to the
overall evaluation, the number of marker genes should be kept below 10.
Indeed, the change of the expression of a single marker gene within a large
set
of marker genes will be of little influence on the overall expression score of
the
marker genes. Based on these arguments and the observed relative
contribution of the different markers identified, it has been determined that
any
number of markers between 3 and 9 is suitable to determine the chondrocyte
phenotypic stability of a cell population or to assess the influence of a
compound or condition on chondrocyte phenotypic stability of a cell
population.
According to one embodiment, a set of 5, 6 or 7 markers is an optimal
compromise between the accuracy of the obtained score from such a set of
markers and the practical feasibility of the assay in high throughput
screening.
One aspect of the present invention thus provides set of at least three
markers representative of cartilage formation selected from the group
consisting
of the positive marker genes FRZB, COL11, COL2, FGFR3, BMP-2, RASF-
PLA2, and OPN and the negative marker genes ALK1 and PEDF.
According to a particular embodiment of the present invention, the set of
at least three markers making up the chondrogenic potential markers, i.e.
representative of cartilage formation includes FRZB, ALK1 and a marker gene
selected from the group consisting of PEDF, COL11, COL2, FGFR3, BMP-2,
RASF-PLA2 and OPN. More particularly, the set of at least three markers
representative of cartilage formation includes FRZB, ALK1 and a marker gene
selected from the group consisting of PEDF, COL11, COL2, and FGFR3.
Further embodiments of the invention relate to sets of at least 4, 5 or 6
marker
genes comprising FRZB, ALK1 and respectively 2, 3 and 4 markers selected
from the group consisting of PEDF, COL11, COL2, FGFR3, BMP-2, RASF-
PLA2 and OPN. More particularly, the sets of at least 4, 5 or 6 marker genes
comprise FRZB, ALK1 and respectively 2, 3 and 4 markers selected from the
group consisting of PEDF, COL11, COL2 and FGFR3. According to a particular
embodiment, a set of six marker genes is used to asses the ability to produce
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
13
stable cartilage in vivo, the set consisting of FRZB, ALK1, PEDF, COL11,
COL2, and FGFR3. The cumulative score of the this set of marker genes
described in Example 1 referred to herein as the llChondroCelectTM markers"
(CC markers) is also referred to as the llChondroCelectTM score".
Alternatively,
the set of markers comprises a variation of this set of chondrogenic potential
markers wherein one of the markers PEDF, COL11, COL2 and FGFR3 is
replaced by one marker selected from the group of RASF-PLA2, OPN and
BMP-2. More particularly, the set of markers comprises a variation of the
above-
described chondrogenic potential markers, wherein one of the positive markers
COL11, COL2 is replaced by either RASF-PLA, OPN or BMP-2. The examples
section herein demonstrates that marker scores based on the expression of the
sets of markers disclosed herein by a chondrogenic cell population reliably
predict the nature of the cartilage produced by the cell population (as
determined by histological analysis).
According to another aspect, the present invention provides methods of
determining chondrocyte phenotypic stability of a cell population. More
particularly, the present invention provides for the use of the sets of marker
genes disclosed herein as a tool in the assessment of chondrocyte phenotypic
stability of a cell population. This is of importance e.g. in the quality
control of
cell populations used in the transplantation of cells in the context of the
treatment of cartilage defects. These methods are characterized in that they
comprise the step of determining the expression by the cell population of a
set
of marker genes as described herein. More particularly, the expression of a
set
of marker genes according to the present invention, optionally expressed as a
cumulative marker score, more particularly the Chondrogenic potential score,
is
used as an indication of the quality of a cell population for implantation
purposes. Typically, the quality assessment of a cell population is performed
in
a laboratory using standard techniques such as those described herein and the
outcome of the assessment is generated in a report or summarized in a quality
control sheet. The cell population may be PO or any passage of a cell
population obtained from a human or animal tissue. According to one
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
14
embodiment, the cell population is between P2 and P6 of a population obtained
from a human cartilage biopsy. Alternatively, the number of population
doublings can be considered. For most cell populations considered in the
context of the present invention, every passage involves 2-3 population
doublings. Accordingly in the context of the present invention, the cell
population is assessed after 1 or two population doublings (PO). Optionally,
the
cell population is a combination of different passages (optionally including
PO)
of cells from one or from different biopsies. Where autologous transplantation
of
cells is intended, the cells obtained from one or more biopsies from a
specific
patient are optionally combined and checked for chondrocyte phenotypic
stability (before and/or after combination thereof). Typically, the quality
assessment is performed at specific time points, i.e. prior to implantation
(as
cells or 2D or 3D tissues in a scaffold or matrix), prior to storage (e.g.
freezing)
and/or retrieval from storage, prior to and/or after subjecting the cell
population
to specific treatments and/or conditions.
Indeed, the object of one aspect of the invention is to determine the
ability of a cell population to produce stable hyaline cartilage in vivo prior
to
either direct implantation, or seeding onto, or encapsulation in a
biocompatible
matrix and subsequent implantation. The marker score is indicative of the
ability
of the cell population or cells to ensure a cartilage implant without signs of
vascular invasion or endochondral bone formation.
Typically, the expression of the markers for determining the marker score
according to the present invention is performed on a cell population as a
whole,
whereby a representative sample is taken to determine, by methods such as
those described herein, whether or not the markers are expressed by the cell
population under investigation. Alternatively, individual cells can be checked
for
the expression of specific genes using cell-specific methods known in the art.
According to another aspect, the invention provides methods for
determining the effect of a compound or condition on the ability of
chondrogenic
cells to produce stable hyaline cartilage in vivo, which methods are of use as
screening tools. These methods comprise the step of contacting a chondrogenic
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
cell population with a compound or condition and, determining the expression
of
a set of marker genes according to the present invention, by that cell
population.
Accordingly, the invention provides methods and assays for identifying
5
compounds or conditions that affect the chondrogenic capacity of a population
of cells. According to one embodiment, the method is used to identify adequate
conditions for cultivating, storing and/or administering cell populations for
transplantation in the context of the treatment of cartilage defects. In such
methods, a chondrogenic cell population is subjected to specific conditions
and
10 the
expression of the marker genes is determined. Typical conditions are
specific cultivation media, cultivation temperatures, cultivation times,
cultivation
density etc.., as well as combinations with other cell types. Additionally or
alternatively, the methods and assays are used for the identification of
molecular factors capable of affecting chondrocyte phenotypic stability of
15 chondrogenic cells. Such factors can include growth factors, mitogens,
additives, small chemical molecules etc... The object of the screening can be
to
identify factors useful in the cultivation, storing or administration of cell
populations for transplantation in the context of the treatment of cartilage
defects. Typically, factors of interest are factors which are capable of
positively
affecting the chondrocyte phenotypic stability of a cell population and/or
factors
which positively affect other features of the cells (e.g., cell number,
stability,
etc..) and/or parameters of the cultivation conditions (e.g., storage time,
number
of passages that can be used, etc..) without negatively affecting the
chondrocyte phenotypic stability of the cell population.
Additionally or alternatively, the assays and methods of the present
invention are of use in the screening and identification of compounds with a
potential effect in vivo on cartilage formation by chondrogenic cells. The use
of
the screening methods of the present invention is envisaged for the
identification of compounds which affect cartilage formation by local cells in
the
body of the patient to be treated and/or cartilage formation by cells used in
the
context of cell transplantation. The screening methods can be used to identify
and/or evaluate compounds which can counteract factors or conditions
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
16
occurring in pathological situations. For instance, cells can be stimulated
e.g.
with IL-1 (to stimulate inflammatory conditions, to enhance catabolic pathways
and to downregulate anabolic processes) before addition of compounds that
potentially counteract this effect.
Also envisaged within the scope of the present invention is the use of the
marker genes for assessing the potential side effects of therapeutic
compounds,
including those used outside the context of cartilage repair, on the ability
of
chondrogenic cells to produce cartilage in vivo. The methods of the present
invention potentially allow the direct identification of effects of compounds
on
bone formation, which, when tested directly in vivo, would only be noticed on
a
longer term.
The methods of the invention relating to the screening of compounds, will
typically comprise the step of contacting a chondrogenic cell population with
one or more compounds of interest and determining the expression of a set of
marker genes as described herein by the chondrogenic cell population. The
methods of the present invention allow high-throughput screening of e.g.
chemical compound libraries, peptide libraries, expression libraries etc...
According to one embodiment, the methods of the present invention
comprise the step of comparing the expression of a set of marker genes
according to a present invention in a cell population to which one or more
compounds has been added/which has been subjected to a particular condition
with the expression of the set of marker genes in the absence of the compound
or condition in the same or a different cell population. In a typical
embodiment,
(a) different fraction(s) originating from the same cell populations are
subjected
to different conditions and/or compounds for comparison with each other and/or
with a positive and/or negative control. The negative control can be a blank
or a
compound known not to affect chondrocyte phenotypic stability. The positive
control can be a compound or condition known to (positively or negatively)
affect the phenotypic stability of a cell population.
In the screening methods of the present invention, different parameters
can be evaluated. Cells can be seeded in individual recipients or multiwell
plates at different densities. Cells can be incubated during different time
periods
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
17
before adding a compound/factor or applying a condition or both. Different
regimes and combinations of compounds and cultivation conditions can be
combined. Compounds/factors can be added at different concentrations and
remain in contact with the cells for different periods of time. The same
applies to
cultivation conditions.
The present invention is based on the observation that the ability of a cell
population to produce hyaline cartilage in vivo after implantation can be
predicted based on the expression of specific genes (the marker genes) by that
cell population in vitro, prior to implantation. Thus, the expression of the
marker
genes is used to monitor the chondrogenic "quality" of the cells prior to
implantation and the effects of compounds and conditions thereon. As detailed
below, the expression of the genes can be expressed as a marker score,
whereby the (relative) expression level of the different marker genes is added
up to obtain a value, which can be compared to the optimal value (i.e. high
expression of all positive markers, low expression of all negative markers
under
consideration). Additionally or alternatively, the screening can take into
account
the ability of the compounds or conditions to influence any one marker within
this set of genes.
Expression of the marker genes of the present invention can be
assessed based on absolute or relative value. Typically, the expression of the
marker gene compared to a house-keeping gene is used. This is exemplified
with actin herein. As the expression levels of different housekeeping genes
may
be different, the skilled person will understand that the relative expression
of the
marker genes compared to the selected housekeeping gene will need to be
established beforehand in a population with chondrocyte phenotypic stability
for
each house-keeping gene used. According to the present invention, the
combined information on the expression of the selected markers is indicative
of
whether or not the cells are capable of cartilage formation in vivo.
The present invention envisages the use of the marker combinations
described herein both in the context of assessing the quality of a given cell
population and for the evaluation of the influence of factors/conditions on
the
ability of cells to produce cartilage after implantation in vivo. Where the
set of
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
18
markers is used to determine the effect of a compound, cell or condition on
the
ability of a cell population to produce hyaline cartilage in vivo, the effect
can be
based on determining 'increased or 'decreased' expression of the marker
genes of the invention relative to a control or relative to the expression
level
prior to contacting the cell population with the compound or condition. In
this
regard, compounds, cells or conditions which increase expression of one or
more positive marker genes and/or decrease the expression of one or more
negative marker genes according to the invention can be considered capable of
positively affecting cartilage formation. Compounds, cells or conditions which
decrease expression of one or more positive marker genes and/or increase the
expression of one or more negative marker genes according to the invention
can be considered capable of negatively affecting cartilage formation.
According to one aspect of the invention, expression of the different
marker genes of the set of markers by a cell population is represented by a
'cumulative marker score', which correlates with and is indicative of the
chondrocyte phenotypic stability of the cell population. The cumulative marker
score is used for the qualitative and/or quantitative interpretation of the
results
in the methods and assays of the present invention.
Different types of marker scores are envisaged within the context of the
present invention. The expression level of a set of markers can be represented
by a numerical value which is/corresponds to the sum of the absolute
expression level of each of the gene products in the marker set. Such
calculation method can be used when a quantitative detection of the expression
of the marker genes is performed e.g. by quantitative PCR or ELISA.
Alternatively, the expression level of each of the genes in the marker set
can be represented by a ratio, i.e. the expression level of a gene is compared
to
that of another gene such as a housekeeping gene which is considered to have
an equal expression level regardless of the treatment of a cell or of which
the
expression is considered as relatively stable, independent of the ability of
the
cell to produce stable hyaline cartilage. This will result in the values of
expression levels for the different markers being more comparable (and mostly
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
19
within the 0.001 to 10 range). Accordingly, the cumulative marker score can be
the sum of the ratios for each marker gene.
According to a particular embodiment of the invention, however, the
cumulative marker score is not based on the absolute or relative values of
expression for each of the marker genes, but on the qualitative assessment of
this expression.
According to a specific embodiment of the present invention, qualitative
assessment of the marker genes is arbitrarily assigned a numerical value, e.g.
'1'. More particularly, according to the present invention, increased/high
expression of the positive markers is assigned the value '1 and absence of
expression of a negative marker is also assigned the value '1'. Most
particularly,
according to the present invention, ranges of expression levels (or ratios of
expression) are defined for both expression levels of positive marker genes
and
expression levels of negative markers of chondrocyte phenotypic stability,
whereby expression levels falling within the predetermined ranges are
attributed
a value. According to a further embodiment, expression values falling outside
the predetermined ranges of expression of the positive and/or negative marker
genes (e.g. when very low expression of a positive marker gene is observed or
very high expression of a negative marker gene) is also attributed a value.
When determining the relative impact of each of the marker genes in the
cumulative marker score, the expression of each gene can have the same
weight. Alternatively, the expression level of one or more genes can be
considered as having a stronger impact on chondrocyte phenotypic stability
than other genes, which can be incorporated in the relative impact of the
marker
genes on the calculation of the cumulative marker score. According to a
specific
embodiment of the invention, the relative impact of the different markers is
the
same and is attributed the value '1' when falling within the predetermined
ranges of expression (or of expression ratios) attributed the value '-1', when
falling outside of the ranges (below or higher than the predetermined ranges
for
the positive and negative markers, respectively). Optionally, the expression
levels within a certain range can be considered to correspond to a value '0',
which corresponds to an expression level of the positive or negative marker
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
gene which does not positively or negatively affect chondrocyte phenotypic
stability in the cell.
In the examples section described herein, a further particular
embodiment of the invention is described. The cumulative marker score
5
representative of a stable cartilage phenotype is determined by a set of up to
six
markers, each of which is attributed equal importance. The expression of each
of the markers is quantified, and a scoring approach based on expression
relative to a marker gene is applied. In this specific embodiment, the score
calculated from these markers is referred to as the "Chondrogenic potential
10
score" i.e. a cumulative marker score which reflects the overall expression of
a
defined set of six markers of cartilage phenotypic stability According to this
embodiment of the invention, the expression level of each gene is determined
via a semi-quantitative method and the obtained values are normalised by
comparison with a reference gene (e.g. beta actin). Thus, an expression level
of
15 1
refers to an expression that is the same as that of actin, an expression level
below 1 refers to an expression that is lower than that of actin (0.1
corresponding to an expression level which is 10x lower than that of beta-
actin)
and an expression level above 1 refers to an expression level that is higher
than
that of actin.
20 In
this specific embodiment of the present invention, the expression level
of each of the marker gene corresponds to one of three possible scores. In the
case of a positive marker (FRZ, COL11, COL2, FGFR3) a very low expression
level (0-0.1) is represented by a score of -1, a low expression level (0.1-1)
is
represented by a score of 0 and a high expression (>1) is represented by a
score of +1. Inversely, for a negative marker (ALK1, PEDF) a very low
expression level (0-0.1) is represented by a score of +1, a low expression
level
(0.1-1) is represented by a score of 0 and a high expression level (>1) is
represented by a score of -1. The sum of all these individual scores
represents
the expression level of the entire set of markers as a whole. For a set of 6
markers, the score can thus range from -6 (all positive markers expressed at a
level which is lower than the reference and all negative markers expressed at
a
level which is higher that the reference gene) to +6 (all positive markers
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
21
expressed at a level which is higher than the reference gene and all negative
markers expressed at a level which is lower than the reference gene). Where
this score is based on the expression of the markers FRZB, COL11, COL2,
FGFR3, ALK1 and PEDF by a cell population, this score is referred to herein as
the ChondrocelectTM score.
As shown in the examples of the present invention, is it possible to
correlate the expression levels of a set of markers, as well as the cumulative
marker score obtained therefrom, with the chondrocyte phenotypic stability of
a
chondrocyte cell population. Accordingly, evaluation of the expression levels
of
a defined set of markers, or of the (cumulative) marker score of a
chondrogenic
cell population upon administration of certain compounds thereto, can be used
to evaluate the ability of the compound to affect chondrocyte phenotypic
stability
of cells and/or the ability of cells to form cartilage in vivo. More
particularly it is
demonstrated that addition of particular compounds to an expanded
chondrocyte cell population improves the Chondrogenic potential score and the
phenotype of this cell population. Negative controls, e.g. addition of
compounds
which promote bone formation decrease the Chondrogenic potential score.
Accordingly, the present invention provides cumulative marker scores
which can be used in a cell-based screening assay to assess the influence of
any factor or condition on the capacity of a chondrogenic population to
produce
stable cartilage. In view of the fact that the cartilage phenotypic stability
of a cell
population as identified in vitro, is representative of the activity of the
cells in
vivo, the assay can be reliably used to identify compounds capable of
influencing cartilage formation by local chondrogenic cells upon
administration
to the cartilage defect. Importantly, the assay and marker analysis as
disclosed
in the present invention do not require a subsequent or parallel in vitro or
in vivo
cartilage formation assay to validate the results, which dramatically shortens
and simplifies large scale screening of compounds.
According to the present invention, the use of a cumulative marker score
is a reliable and efficient tool to evaluate chondrocyte phenotypic stability
of a
cell population and/or to assess the effect of conditions or compounds on the
chondrocyte phenotypic stability of chondrogenic cells. The reliability of the
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
22
score is determined on the one hand by the correlation between positive scores
and the ability to generate phenotypically stable cartilage in vivo and the
correlation between negative scores and the fact that the cells are not
capable
of generating phenotypically stable cartilage in vivo. An additional desirable
requirement of a reliable cumulative marker score is its efficiency, i.e. its
ability
to efficiently distinguish populations that are and populations that are not
capable of generating phenotypically stable cartilage in vivo. For instance,
where the number of markers is six, and the scoring system varies between +6
and ¨6, as described above, there is typically a "grey zone" (populations
characterized by a cumulative marker score of a range located between +6 and
-6), for which the cumulative marker score is not unequivocal and which, when
tested would be found to comprise both populations that are and populations
that are not capable of forming stable hyaline cartilage. Ideally, the marker
score will result in a minimal number of populations in that grey zone, but
will
allow a maximally efficient classification of populations either as "positive"
or as
"negative".
More particularly, in the context of determining chondrocyte phenotypic
stability of a cell population used for transplantation, both the reliability
and the
efficiency of the cumulative marker score can be critical, so as to allow a
straightforward and correct determination of fate of the cell population.
Indeed,
the use of a cumulative marker score of a relatively low predictive value for
characterizing a population of cells intended for transplantation is of
limited
value as it does not allow to decide upon implantation or not. For such
applications, the use of the Chondrogenic potential score of the present
invention as a scoring tool is considered particularly appropriate, in view of
its
high reliability and efficiency. It is however envisaged that for use in
screening,
the efficiency of the predictive value may be less critical. As indicated
above, a
potential purpose of the screening assays of the present invention is to
identify
pharmaceutical compounds that affect, more particularly improve, the
chondrocyte phenotypic stability of a cell population. Thus, in such screening
methods, the relative improvement of chondrocyte phenotypic stability can be
envisaged to be the critical requirement rather than the ability of the
compounds
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
23
to induce or maintain a perfect chondrocyte phenotypic stability. For example,
it
is envisaged that upon performing a screening assay, the compounds capable
of converting low quality cells (no cartilage after implantation) into
intermediate
quality cartilage (cells having a score which can not be used to predict
unequivocally the result of after implantation), will also be considered of
interest.
The cell populations that are used in the methods and assays of the
present invention include any cells that are believed to be capable of
producing
cartilage or that can develop into cartilage producing cells. Typically, the
cells
are osteochondral cells, such as chondrocytes and their precursor or
progenitor
cells obtained from articular cartilage, meniscus or synovial fluid. According
to
one embodiment, the cells used in the context of the present invention are the
precursor cells described in W001/25402. In some embodiments the cell
population are precursor cells or stem cells that are derived from other
tissues
such as blood bone marrow or fat and that can be induced into the
osteochondral cell lineage. The assays of the present invention can be used to
determine whether these cells have been committed to the osteochondral cell
lineage.
The cells used in the screening methods and assays of the invention can
be freshly isolated, expanded or passaged for one or more passages. The cells
can be present as cell cultures either in culture flasks or present on a
matrix or
scaffold. The expression of the set of markers by cells on a matrix can be
determined by dissolving the matrix and determining the expression by the
cells. Cells can be of human or animal origin. Examples of animals that have
been used for the study of cartilage are Xenopus, zebrafish, chicken, mouse,
rat, rabbit, sheep and goat.
The methods and assays of the present invention can be performed with
cells, which have a stable chondrocyte phenotype as a result of their origin
and/or the cultivation conditions. Such cells are of particular use to assay
detrimental effects of a given compound, treatment or condition.
According to an alternative embodiment, the methods and assays of the
present invention are performed using cells that do not have a stable
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
24
chondrocyte phenotype or that have lost the chondrocyte stable phenotype, as
a result of their origin and/or cultivation conditions. Examples hereof are
chondrocytes that have undergone extensive passaging and stem cells. Also
suitable are chondrocytes derived from individuals with an osteochondral
defect
such as (resulting from) osteoarthritis or rheumatoid arthritis or from
individuals
which are predisposed to acquire a osteochondral disorder based on to their
genetic makeup. Also suitable are cartilage tumour cells or chondrosarcoma
cells.
Cells not having chondrocyte phenotypic stability are of particular use in
the methods of the present invention to screen for compounds or conditions
that
improve or restore the stable cartilage phenotype of cells, or that can
convert
certain cell populations such as stem cells into cells with stable cartilage
phenotype.
The present invention envisages the use of the methods and assays of
the present invention in a variety of different applications. As detailed
above, the
methods and assays of the present invention make it possible to test
cultivation
conditions of cells intended for use in ACT such as cell density, passage
number, medium composition, growth in or on two- or three-dimensional
substrates, oxygen concentration, pressure, shear stress. In particular the
assay allows the testing of the influence of the composition of the medium on
chondrocyte phenotypic stability. Factors therein which potentially have an
impact on the chondrocyte phenotypic stability include, but are not limited
to,
the type and batch of serum, different formulations of synthetic serum-free
media, and a variety of hormones, growth factors, vitamins, proteins and
organic compounds with a alleged effect chondrocyte phenotypic stability.
One application of the methods and assays of the present invention is
the screening of compounds or conditions, which differentiate precursor or
stem
cells into the osteochondral and more particularly in the chondrogenic
lineage.
Another application is the screening of compounds or conditions which can
restore or maintain the chondrocyte phenotypic stability of healthy cells that
have been or are being passaged many times, respectively, so as to obtain a
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
sufficient number of cells. Yet another application is the screening of
compounds or conditions which can induce chondrocyte phenotypic stability in
cells which are obtained from individuals having or predisposed to an
osteochondral defect.
5 In
another application, the assay is used to evaluate the impact of
matrices, scaffolds, gels or their constituents, which are often used in cell
transplantation procedures.
The methods and assays of the present invention are also suitable in
classical screenings of peptide libraries, antisense libraries or compound
10
libraries. The compounds making up these libraries include, but are not
limited
to biologicals and organic or inorganic compounds, which are produced
synthetically or obtained from natural sources. Examples hereof are libraries
of
compounds may be used such as antibody fragment libraries, peptide phage
display libraries, peptide libraries (e.g.LOPAP #, Sigma Aldrich), lipid
libraries
15
(BioMol), synthetic compound libraries (e.g.LOPAC@, Sigma Aldrich) or natural
compound libraries (Specs, TimTec).
The screening methods and assays described herein are of particular
use in the identification of lead compounds for medicaments for the treatment
of
osteochondral disorders. Osteochondral defect envisioned to be of interest in
20 the
context of the screening methods of the present invention include, but are
not limited to defects occurring in the joints, such as, but not limited to
knee,
elbow, ankle, commonly referred to as articular cartilage defects. Cartilage
defects are also named after the proximal bone such as defects of the condyles
of the femur, of the humerus etc. Frequently occurring cartilage disorders,
for
25 which
the screening of compounds capable of affecting chondrocyte phenotypic
stability are envisaged to be of interest are osteoarthritis, rheumatoid
arthritis,
articular cartilage injuries, chondromalacia, spondyloarthropathies.
Brief description of the Figures
The following examples are intended to illustrate the invention without
implying
any limitation of the invention to the specific embodiments described therein.
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
26
These examples are illustrated by the following Figures in which,
Figure 1 shows a scatter plot of histology score against Chondrogenic
potential
score (each point has been moved by a small random amount and
direction in order to avoid points being superimposed).
Figure 2 shows the effect of compound A on the cumulative marker score (the
CC score as determined in Example 1) as determined by Real-Time
quantitative PCR on human chondrocytes cultured from PO until P3
in monolayer. Results represent mean cumulative marker score
relative to a control (DMSO). *p<0.05 when compared to DMSO
control (n=4).
Figure 3 shows the effect of compound A on the expression of molecular
markers COL2 (A), COL11(B), FRZB (C) and FGFR3 (D) positively
correlated with the chondrogenic potential of human P3 chondrocytes
cultured in monolayer as determined by Real-Time quantitative PCR.
Results represent target gene expression relative to the DMSO
control as determined by the 2-deltadeltaCT. *p<0.05 when compared to
DMSO control (n=4).
Figure 4 shows the effect of a compound A on the expression of molecular
markers PEDF (A) and ALK1 (B) negatively correlated with the
chondrogenic potential of human P3 chondrocytes cultured in
monolayer as determined by Real-Time quantitative PCR. Results
represent target gene expression relative to DMSO control as
determined by the 2-deltadeltaCT. *p- <0.05 when compared to DMSO
control (n=4).
EXAMPLES
Methodology
Chondrocyte cultivation
Chondrocytes derived from adult human articular cartilage were isolated and
expanded in vitro using standard conditions as described by Dell'Accio et al.
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
27
(2001), Arthritis Rheum. 44, 1608-1619).
In vivo assay
The markers of the present invention were validated using a set of 48
chondrocyte samples which were obtained from different persons and were
freshly isolated or passaged for 1 up to 5 passages. A part of the
chondrocytes
were used for marker analysis (see example 3) while another part was used in
an in vivo assay to verify the cartilage forming capacity of each sample.
Female
NMRI nu/nu mice were injected intramuscularly (posterior compartment of the
thigh) with about 5 million human cells. Implants are collected after 2 weeks.
[Lipman et al. (1983) Ca'cif. Tissue Int. 35, 767-772; Ostrowski et al. (1975)
Somatic Cell Genet. 1, 391-395]. The cartilage implants were dissected from
the muscle and histology was performed using hematoxilin-eosin, toluidin blue
and Safranin 0 staining. A histology score ranging from 1 to 3 is attributed
to
the implant after staining. A histology score of 3 refers to hyaline-like
cartilage
with highly sulfated proteoglycans, strong staining with toluidine blue and
Safranin O. A histology score of 2 refers to well differentiated hyaline-like
cartilage, strong staining with toluidine blue, weak staining with Safranin O.
A
histology score of 1 refers to "fibrocartilage", undifferentiated fibrous
tissue, no
or weak staining with toluidine blue. A histology score of 0 refers to
experiments
wherein no implant was retrieved. Cartilage with a histology score of 2 or 3
represents successful implantations. Cartilage with a histology score of 0 or
1
represent failed implantations.
Example 1: Marker analysis
A fraction of the injected cells was used for gene expression analysis. RNA
isolation, reverse transcription and PCR were performed using the methods
described in W00124832. PCR primers for these markers are shown in Table1.
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
28
Table 1: Primers for the amplification of marker genes
Primer Sequence
SEQ ID. NO:
beta actin forward 5'-tgacggggtcacccacactgtgcccatcta-3 1
reverse 5'-ctagaagcatttgcggtggacgatggaggg-3' 2
Collagen 11 forward 51-gaactccatctctccctgc-31 3
reverse 5'-gagactggatttcaaggcaag-3' 4
Collagen 2 forward 51-ccctgagtggaagagtggag-3' 5
reverse 5'-gaggcgtgaggtcttctgtg-3' 6
PEDF forward 5'-ttcaaggggcagtgggtaac-3' 7
reverse 5'-taaggtgatagtccagcggg-3' 8
Frzb1 forward 5'-tgtaagtctgtgtgcgagcg-3' 9
reverse 5'-g a ttta g ttg cg tg cttg cc-31 10
ALK1 forward 5'-cgacggaggcaggagaagcag-3' 11
reverse 5'-tgaagtcgcggtgggcaatgg-3' 12
FGFR3 forward 5'-gctgaaagacgatgccactg-3' 13
reverse 5'-aggaccccaaaggaccagac-3' 14
The expression levels of the markers are determined by measuring the intensity
of PCR products after electrophoresis. All values are then compared relative
to
a 600 bp band of a DNA-marker and a value is obtained. The concentration of
the individual markers is represented by a numerical value. In the case of a
positive marker (COL11, COL2, FGFR3) a very low expression (0-0.1) is
represented by -1, a low expression (0.1-1) is represented by a 0 and a high
expression is represented by +1. On the contrary In the case of a negative
marker (ALK1, PEDF) a very low expression (0-0.1) is represented by +1, a low
expression (0.1-1) is represented by a 0 and a high expression is represented
by -1. The sum of all these individual markers (defined as Chondrogenic
potential score) represent the expression level of the entire set of markers.
This
number can range from -6 to +6.
The individual data for each marker, its Chondrogenic potential score and
histology score are compiled in Table 2.
Table 2: Overview of histology scores and Chondrogenic potential scores
performed on respectively cartilage
implants and injected chondrocytes. Sample codes refer to a patient code, a
passage number and eventually the
confluency of the cells.
o
w
=
=
Positive markers
Negative markers oe
'a
c.,
oe
Sample Sample code Histology ChondroCelect COL11 COL2 FGFR3
FRZB ALK1 PEDF =
.6.
score score
1 cs29p0 3 5 3.94 8.25 3.34
4.17 0.16 0
2 cs49p0 80% 3 5 0.66 1.93 1.90
2.26 0 0
3 Cs141p3 3 4 1.44 6.10 3.22
2.85 0.61 0.41
4 cs22p0 3 4 5.45 10.89 6.38
5.06 0.66 0.58
7 Cs141p0 3 3 4.95 10.95 0.34
4.42 0.39 0.35
n
8 Cs145p0 3 3 5.51 8.46 4.18
8.28 0.79 2.56
9 Cs148p0 3 3 2.32 11.63 3.90
6.28 0.52 1.14 0
I.,
0,
cs28p0 3 3 2.63 9.02 4.00 4.77
0.41 1.12 -,
0
11 cs49p0 100% 3 3 3.63 1.75 3.78
2.49 1.22 0.84
H
N.)
lo
5 Cs126p1 3 2 2.99 3.28 2.29
1.68 1.39 1.39
12 Cs130p0 3 2 11.96 10.77 4.87
10.89 1.23 1.83 0
0
ko
'
13 Cs134p1 3 3 10.8 7.82 1.81
1.291 0.960 1.54 0
u-,
14 Cs141p2 3 2 7.27 13.60 0.02
5.17 0.78 0.54 1
I.,
Cs145p3 3 2 0.10 2.53 2.35 1.10
0.22 0.31 "
16 Cs146p0 3 2 0.11 7.25 2.21
2.50 0.61 1.05
17 cs49p1 90% 3 2 0.51 0.18 1.53
1.21 0.20 0.43
6 Cs136p1 3 1 0.81 1.14 0.44
0.48 0.42 0.37
18 Cs137p3 3 1 0.63 3.19 1.64
0.87 1.01 0.81
19 Cs145p2 3 1 3.19 5.08 0.29
3.97 1.73 1.60 Iv
n
Cs146p1fbs 3 1 1.47 2.00 0.79 1.61
1.57 3.82
21 Cs130p2 3 0 8.14 0.43 0.90
1.32 1.30 3.18 m
Iv
22 Cs142p1 3 0 0.12 3.50 0.94
1.30 1.03 1.38 w
=
=
23 Cs113p1 2 4 3.00 3.89 3.54
1.02 0.80 0.38 -4
=
24 cs55p1 2 3 1.24 3.93 1.01
1.70 0.22 3.67
o
w
Cs134p2 2 2 8.18 14.54 1.99 2.45
3.09 1.33 oe
u,
Positive markers
Negative markers
Sample Sample code Histology ChondroCelect COL11 COL2 FGFR3 FRZB ALK1
PEDF o
score score
w
=
26 Cs127p1 2 2 6.85 10.48 0.82
3.08 0.84 1.83 =
oe
27 Cs137p4 2 2 0.34 1.73 0.87
1.04 0.57 0.84 'a
o,
,-,
28 Cs141p5 2 2 0.37 4.23 5.22
2.28 1.06 0.30 oe
o
.6.
29 cs28p1 2 2 1.20 0.53 0.90
0.65 0.52 0
30 cs43p1 2 2 1.67 0 1.16
0.74 0.40 0
31 cs43p0 2 1 0.64 0 1.46
0.84 0.13 0
32 cs41p1 2 0 0.44 0.05 1.18
0.55 0.25 0.35
33 Cs148p3 2 -1 0.31 0.87 1.63
0.88 1.36 1.63
34 Cs139p1 2 -2 0.44 0.15 0.02
0.55 0.93 2.33
35 Cs110p3 1 1 1.21 1.08 2.89
0.31 2.37 2.42 n
36 Cs127p3 1 -1 4.22 1.05 0.01
0.89 1.42 7.72 0
I.,
0,
37 cs22p1 1 -1 0.45 0.33 0.42
2.41 1.23 9.22 -,
0
38 cs41p2 1 -1 1.26 0 1.72
0.71 1.87 4.42
H
CA.1
ko
39 Cs145p5 1 -2 0.15 0.23 0.56
0.50 2.86 2.42 = o I.)
40 Cs41p3 1 -2 0.95 0 1.34
0.23 1.12 4.34 0
0
ko
'
41 Cs125p5 1 -3 3.17 0 0
0.13 3.87 9.02 0
42 Cs134p5 1 -4 0.07 0.09 0.35
0.34 1.73 1.37
1
I.)
43 Cs146p3 1 -5 0.07 0.01 0.06
0.15 1.65 2.67 "
44 cs43p2 0 -1 2.56 0 0.13 0.2
1.29 0.41
45 Cs110p5 0 -4 0.54 0.0 0.2 0.0
1.7 7.9
46 Cs41p4 0 -3 0.14 0 0.38
0.11 1.17 1.74
47 Cs146p5 0 -4 0.07 0.14 0.08
0.14 2.13 3.46
48 Cs148p5 0 -4 0.05 0.02 0.16
0.14 1.57 2.34 oo
n
1-i
m
oo
w
=
=
-4
=
,-,
=
w
oe
u,
CA 02670419 2009-05-22
WO 2008/061804
PCT/EP2007/010285
31
Example 2: Data analysis
The correlation between the Chondrogenic potential score as determined in
Example
1 and the histology score is depicted in Table 3 and in Figure 1. The
correlation
coefficient between the Chondrogenic potential score and histology score is
0,78 and
statistically significant (p<0.0001).
Samples with a Chondrogenic potential score of -3 or lower always result in
fibrocartilage or no cartilage at all. Samples with a Chondrogenic potential
score of 2
or more will always result in hyaline cartilage. Samples with a Chondrogenic
potential
score of 1 results in 1 out of 6 cases into hyaline cartilage.
As a yardstick, a sample with a Chondrogenic potential score of 0 or more is
considered to be suitable for implantation. Based on the present data set it
is
possible to predict in 77% (37/48) the outcome of a transplantation with high
certainty
and in 64% without errors. Based on this data set, a chondrocyte culture is
approved
for use in an ACI procedure when the Chondrogenic potential score is 0 or
more.
In summary, stable hyaline-like cartilage can only be obtained with cells
having a
Chondrogenic potential score of 0 or higher. Cells that form no cartilage at
all had a
negative score. Further analysis of individual genes may further help to
refine the
model.
a) relationship between Chondrogenic potential score and histology score
The relationship between Chondrogenic potential score and histology score is
depicted in Figure 1 and in Table 3.
Table 3: Frequency table for histology score, with statistical summaries.
Chondro-probability of score of
histology score
Celect > 2
score 0 1 2 3 Total Mean Observed Fitted
-5 0 1 0 0 1 1.0 0/1
(0%) 0.4%
-4 2 1 0 0 3 0.3 0/3
(0%) 1.4%
-3 2 1 1 0 4 0.75 1/4
25% 5.0%
-2 0 2 0 0 2 1.0
O/2(0%) 16.2%
-1 1 3 1 0 5 1.0
115(20%) 41.5%
0 0 0
1 2 3 2.7 3/3(100%) 72.4%
CA 02670419 2009-05-22
WO 2008/061804
PCT/EP2007/010285
32
1 0 1 1 4 6 2.5 5/6 (83%)
90.6%
2 0 0 6 6 12
2.5 12/12(100%) 97.3%
3 0 0 1 6 7 2.9 7/7(100%) 99.2%
4 0 0 1 2 3 2.7 3/3(100%) 99.8%
0 0 0 2 2 3.0 2/2 (100%) 99.9%
Total 5 9 12 22 48
In addition to the frequency table, Table 3 also shows the mean histology
score for
each value of the Chondrogenic potential score. This mean value increases
significantly (from 1.0 to 2.7) between Chondrogenic potential scores of -1
and O.
This suggests to consider samples with a Chondrogenic potential score of 0 or
higher
as suitable for ACI.
b) Data analysis using a categorical scale
An "ordered categorical scale is a scale in which the categories are numbered
purely
to show their sequence: the actual numbers assigned provide no other
information.
For example, the histology scale here takes values of 0, 1, 2, 3. Interpreting
this as
an ordered categorical scale implies that 1 is better than 0, but says nothing
about
how much better. For an interval scale, however, the actual numbers are
regarded as
meaningful, wherein 1 is better than 0 by the same amount that 2 is better
than 1,
etc. In calculating mean values as in Table 3, the implicit assumption is made
that the
histology score can be validly treated as an interval scale.
The more points a scale has, the more it is accepted that such scale is an
interval
scale. The Chondrogenic potential score which is represented by 13 data points
is
accordingly treated as an interval score.
An additional analysis is presented in the last column of Table 3, which
treats the
histology score as an ordered categorical scale. Herein the scores are merged
into
two categories, 0 or 1 (no or low fibrocartilage) and 2 or 3 (hyaline
cartilage), the data
represent the probability of observing a histology score of 2 or 3. It
In the last two columns of Table 3, the column headed 'observed shows the
actual
numbers of samples in this category (and the percentages) for each
Chondrogenic
potential score. This value also increases between Chondrogenic potential
scores -1
and 0, suggesting a threshold value cut-point. For this analysis the
Chondrogenic
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
33
potential score is considered as and ordered categorical scale.
c) Data analysis using an interval scale
When the Chondrogenic potential score is treated as an interval scale, the
observed
responses can be smoothed out using logistic analysis. This method predicts
the
probability of being in the desired category (2 or 3). The fitted values do
not go
outside the plausible range (0 to 100%). These fitted values are shown in the
final
column of Table 3, and shows the effect of smoothing. These fitted estimates
are
assumed to provide a more reliable prediction of the chance of getting a 2 or
3
histology score at any given Chondrogenic potential score than by other
methods.
Note that in particular for a Chondrogenic potential score of -1, the fitted
model is
predicting a chance of 41.5% of getting a 2 or 3, and consequently, this
raises the
question of whether a score of -1 should be accepted.
Example 3. Impact of individual markers
The impact of individual markers is assessed by recalculating the expression
profile
of 5 markers instead of 6 markers of the set of markers determining the
Chondrogenic potential score in Example 1. The same scoring system was
applied,
wherein scores now can range from -5 to +5.
Data are presented in Tables 4 to 9.
Table 4: Frequency table for histology score without COL11 marker
Marker Histology score
score 0 1 2 3 Total
-5 0
-4 1 2 3
-3 3 1 4
-2 1 4 1 6
-1 1 1 1 3
0 1 1 3 5
1 5 5 10
2 3 8 11
3 1 3 4
4 1 1
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
34
5 1 1
total 5 9 12 22 48
Table 5: Frequency table for histology score without COL2 marker
Marker Histology score
score 0 1 2 3 Total
-5
-4 1 1 2
-3 2 1 3
-2 1 3 1 5
-1 2 1 1 4
0 1 2 5 8
1 6 5 11
2 = 3 7 10
3 1 2 3
4 2 2
5 9 12 22 48
Table 6: Frequency table for histology score without PEDF marker
Marker Histology score
score 0 1 2 3 Total
-5
-4 1 1
-3 3 1 4
-2 1 1 2
-1 1 2 1 4
0 3 2 5
1 2 4 6
2 1 3 5 9
3 2 5 7
4 2 8 10
5
5 9 12 22 48
Table 7: Frequency table for histology score without FRZB marker
Marker Histology score
score 0 1 2 3 Total
-5 1 1
-4 2 1 3
-3 2 1 3
CA 02670419 2009-05-22
WO 2008/061804
PCT/EP2007/010285
-2 3 1 4
-1 1 2 1 2 6
0 1 2 3
1 1 5 8 14
2 3 6 9
3 1 2 3
4 2 2
5
5 9 12 22 48
Table 8: Frequency table for histology score without ALK1 marker
Marker Histology score
score 0 1 2 3
-5
-4 1 1
-3 3 1 4
-2 1 1 1 3
-1 2 2
0 1 3 2 6
1 1 3 4
2 1 4 7 12
3 3 7 10
4 1 4 5
5 1 1
5 9 12 22 48
Table 9: Frequency table for histology score without FGFR3 marker
Marker Histology score
score 0 1 2 3 Total
-5
-4 2 2 4
-3 2 1 3
-2 3 1 4
-1 1 1 2 4
0 2 1 3 6
1 3 8 11
2 4 5 9
3 , 1 4 5
4 2 2
5
5 9 12 22 48
CA 02670419 2009-05-22
WO 2008/061804
PCT/EP2007/010285
36
Part A of Table 10 below indicates for each of the data sets presented in
Table 4 to 9
above, for a threshold of a marker score, how many of the samples can be
unequivocally classified as giving low quality (histology score of 0 or 1
corresponding
to - in Table 10) or giving high quality cartilage (histology score of 2 or 3,
indicated
by +' in Table 10). Samples for which there is no correlation between the
marker
score and histology score are classified as ?' samples. These data indicate
that
when a set of 5 markers is used wherein COL11, COL2 or COL11 or omitted,
similar
or even better results are obtained (i.e. fewer samples designated as '7).
In part B of Table 10 the cut off values are less restricted. When for one
marker score
within the indicated range, at least 5 out of 6 samples show a correlation
between
marker score and cartilage quality, the range of the marker score is assumed
to be
predictive. Using this approach omission of COL11 results in improved results
while
omission of any other marker gives worse results, especially when Co12 or
FGFR3
are omitted from the markers set of Example 1.
Table 10: Predictive values of a marker set containing 5 markers.
A 6
markers -COL11 -COL2 -PEDF -FRZB -ALK1 -FGFR3
7 7 5 7 7 5 7
17 14 17 24 27 27 14
24 27 26 17 14 16 27
6 markers -COL11 -COL2 -PEDF -FRZB -ALK1 -FGFR3
7 13 10 7 7 5 7
8 3 12 9 10 11 14
33 32 26 32 27 32 27
Based on the present set of data and their interpretation, it appears that the
predictive power of the expression profile of a set of markers for the in vivo
generation of cartilage can optionally also be obtained without COL11
regardless of
the interpretation. On the other hand omission of either ALK1 or FRZB results
in a
decreased predictive power of the markers, regardless of the interpretation of
the
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
37
present data set.
Example 4. Use of the marker score in screening assays
The evaluation of chondrocyte phenotypic stability using a cumulative marker
score
was tested in screening assays to identify compounds capable of affecting the
ability
of cells to produce stable cartilage in vivo and to determine the nature of
the effect of
such compounds on the cells.
Screening assays were performed in 96 well plates wherein between 10 000 and
100
000 chondrocytes obtained from a cartilage biopsy were seeded (freshly
isolated
from passage 0 to P5). Test compounds were added in varying concentrations and
for varying time periods. After incubation, chondrocytes were harvested, RNA
was
isolated and treated with reverse transcriptase. Quantitative PCR was
performing
according to the instructions of the TaqMan procedure, and the Chondrogenic
potential score of the cells was determined as described in Example 1 (CC
score).
1. Testing for molecules that counteract the dedifferentiation of chondrocytes
in
monolayer culture
Compound A was a candidate compound which was predicted to have a
chondroprotective effect and to have a putative stabilizing effects on the
chondrocyte
phenotype. The determination of a cumulative marker score, more particularly
the
chondrogenic potential score of Example 1, was used to determine the effect of
this
compound on the chondrocyte phenotypic stability of a chondrocyte monolayer
culture.
a) Chondrocyte monolayer cultures
Chondrocytes were grown in monolayer culture at 4x104 cells/ml in T25 flasks.
Compound A was added to the cells directly after plating. A total final volume
of 5 ml
complete media (DMEM + 10% FBS) was added. Three flasks were used for each
condition (1 or 10pM compound A, DMSO control). Media and compounds were
replaced once a week. At confluency, chondrocytes at passage 0 (PO) were
trypsinized, counted and 2x105 cells were replated for P1 culture. The
remaining cells
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
38
were put in lysis media for RNA extraction. The same procedure was performed
for
P1, P2 and P3 chondrocyte cultures. TaqMan RT-PCR was used to determine the
expression of chondrogenic markers.
b) RNA isolation, cDNA generation
Chondrocytes obtained from monolayer culture were washed with PBS and lyzed
using RLT buffer containing 1% mercaptoethanol (Qiagen). Lysed cells were
stored
at -80 C until used. mRNA was purified using the RNeasy microkit (Qiagen)
according to the manufacturer instructions. cDNA was synthesised using random
hexamers following the manufacturer instructions (Invitrogen).
c) TaqMan real time polymerase chain reaction (RT-PCR)
Real-Time quantitative PCR (RT-PCR) was performed using the ABI prism 7700
sequence detector system. The Mastermix qPCR kit (Eurogentec) was used for RT-
PCR according to the manufacturer's instructions. The primers and probes used
for
the TaqMan analysis were ordered from Applied Biosystems or Eurogentec. Real-
Time PCR data were calculated using the 2-deltadeltaCT (2DDCT) method which is
defined as the amount of target gene normalised to an endogenous reference (13-
actin) and relative to a calibrator, which in this case are the expression
levels of
selected genes under control conditions (DMSO).
d) Results
Compound A had an effect on the expression of several molecular markers
indicative
for the chondrogenic capacity, phenotypic stability and homeostasis of
chondrocytes
and was able to counteract the decrease in the chondrogenic potential score
during
expansion of chondrocytes in monolayer culture (see Figure 2) Thus both at 1pM
and
10pM concentrations, the chondrogenic potential scores for chondrocytes at PO
and
P3 were comparable or even increased compared to chondrocytes grown in the
absence of the compound. In the latter case a drop in cumulative marker score
was
observed for P3 versus PO chondrocytes.
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
39
Compound A had a positive effect on the gene expression of several of the
extracellular matrix components of chondrocytes. At lower (1pM) but not higher
(10pM) concentrations, compound A induced the expression of both Co12 and
Co111
gene transcripts (Figure 3). The compound also increases the expression of the
FGFR-3 marker although the increase was not statistically significant.
Moreover,
compound A strongly inhibited the expression of PDEF at both concentrations
tested
(Figure 4). At 10pM, the addition of the compound also resulted in a reduced
expression of ALK1 (Figure 4). Both markers, when upregulated, correlate
negatively
with the chondrogenic capacity of the cells indicating that compound A has a
positive
and stimulatory effect on the chondrogenic potential of the chondrocytes cells
and
thus on chondrogenesis.
2. Screening molecules for their ability to mediate the re-differentiation of
de-
differentiated chondrocytes in 3D culture.
Fourteen compounds were screened for their ability to enhance the re-
differentiation
of dedifferentiated chondrocytes in alginate cultures. The effect of the
molecules on
the expression of the different molecular markers and on the cumulative marker
score (chondrogenic potential score as determined in Example 1) were
determined,
in order to assess the ability of the compounds to affect the recovery of the
chondrogenic phenotype of the cells in the 3D cultures.
a) Redifferentiation of chondrocytes in alginate culture
After expansion in monolayer culture in complete media, human chondrocytes at
passage 3 (P3) taken from the knee of 5 OA patients (age 50-65) were released
by
trypsin treatment, counted and tested for viability by the trypan exclusion
test.
Chondrocytes were suspended in 2% alginate and equal amount of HBSS was
added. The cell suspension was sucked into a 10m1 syringe needle and
transferred
dropwise by a 24 Gauge into a calcium chloride solution (5 beads per well,
total cell
number 250000/well). Beads were washed with NaCI and new complete media
(DMEM + 10% FBS) was added. After 4 days of culture the supernatant was
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
removed and new media was added with the compounds at a concentration of 10pM.
Four days after addition of the compounds, the supernatant was removed and the
cells were released from their beads for lysis. mRNA and cDNA were generated
and
TaqMan RT-PCR were used to measure the expression of COL2, COL11, FGR3,
FRZB, ALK1, PEDF as described in Example 1.
b) Results
The relative effects of the compounds on the up or down regulation of marker
gene
expression in chondrocytes grown in alginate is summarized in Table 11. The
effects
are relative to chondrocytes grown in the absence of molecules (but presence
of
vehicle DMSO). Results represent the mean expression (mean of 5 OA patients)
relative to controls (chondrocytes plus DMSO). NS = not significant; - =
inhibits; + =
enhances; # = p<0.05 significant when compared to control DMSO. Compounds
were used at 10 pM.
Several molecules were able to affect the expression of various marker genes
in a
positive or negative way. Only two compounds (Cpd 8 and Cpd 14) had a positive
effect on the cumulative marker score (CC score) indicating that these
compounds
could enhance/mediate re-differentiation of the chondrocytes. However, only
Cpd 14
had the desired effect on each of the individual markers, with no effect on
BMP2 or
ALK1 gene expression. This compound could be useful in stimulating chondrocyte
de-differentiation ex vivo before re-implantation and could thus tip the
balance
towards formation of articular hyaline cartilage in vivo.
=
CA 02670419 2009-05-22
WO 2008/061804 PCT/EP2007/010285
41
Table 11. Effect of test compounds on the expression of phenotypic
modulation of dedifferentiated chondrocytes grown in alginate cultures.
compounds COL2 FGR3 BMP2 COL11 ALK1 PEDF CC
score
Cpd 1 NS # NS NS NS -* _ NS
Cpd 2 # NS # NS NS -# NS
Cpd 3 _ # # NS # NS - * NS
Cpd 4 _ # NS NS NS NS NS NS
Cpd 5 _ # # # NS NS
Cpd 6 # _ # # NS NS
Cpd 7 NS # NS NS NS NS NS
Cpd 8 NS NS NS # # NS + #
Cpd 9 NSNS NS NS NS NS NS
Cpd 10 # NS NS NS NS NS NS
Cpd 11 _ # # + # NS NS
Cpd 12 _ # NS + # NS _ # _ # NS
Cpd 13 _ # NS NS NS NS - # -#
Cpd 14 +# + # NS + # NS - # +#
Example 5. Testing of the effect of chondroprotective compounds in vivo
For those compounds of Example 4 significantly affecting the Chondrogenic
potential
score, the effect of the compounds on the chondrocyte phenotypic stability of
the
cells is also tested in vivo. To this end, cell populations are contacted with
either the
test compound or buffer and, after incubation, are injected into the nude mice
model
(see above). The ability of each of the cell populations to produce stable
hyaline
cartilage is evaluated. It is established that the effect of the compound on
the
chondrogenic potential score correlates with the effect on the chondrogenic
potential
of the cell population.
CA 02670419 2009-05-22
41a
SEQUENCE LISTING IN ELECTRONIC FORM
In accordance with Section 111(1) of the Patent Rules, this description
contains a sequence listing in electronic form in ASCII text format
(file: 77770-146 Seq 17-APR-09 v1.txt).
A copy of the sequence listing in electronic form is available from the
Canadian Intellectual Property Office.
The sequences in the sequence listing in electronic form are reproduced
in the following table.
SEQUENCE TABLE
<110> Tigenix N.V.
Luyten, Frank
De Bari, Cosimo
Dell'Accio, Francesco
<120> Marker genes for use in the identification of chondrocyte
phenotypic stability and in the screening of factors influencing
cartilage production
<130> T4503-PCT
<150> US 60/867,152
<151> 2006-11-24
<160> 14
<170> PatentIn version 3.3
<210> 1
<211> 30
<212> DNA
<213> artificial sequence
<220>
<223> PCR primer
<400> 1
tgacggggtc acccacactg tgcccatcta 30
<210> 2
<211> 30
<212> DNA
<213> artificial sequence
<220>
<223> PCR primer
<400> 2
ctagaagcat ttgcggtgga cgatggaggg 30
CA 02670419 2009-05-22
41b
<210> 3
<211> 19
<212> DNA
<213> artificial sequence
<220>
<223> PCR primer
<400> 3
gaactccatc tctccctgc 19
<210> 4
<211> 21
<212> DNA
<213> artificial sequence
<220>
<223> PCR primer
<400> 4
gagactggat ttcaaggcaa g 21
<210> 5
<211> 20
<212> DNA
<213> artificial sequence
<220>
<223> PCR primer
<400> 5
ccctgagtgg aagagtggag 20
<210> 6
<211> 20
<212> DNA
<213> artificial sequence
<220>
<223> PCR primer
<400> 6
gaggcgtgag gtcttctgtg 20
<210> 7
<211> 20
<212> DNA
<213> artificial sequence
<220>
<223> PCR primer
<400> 7
ttcaaggggc agtgggtaac 20
.
.
CA 02670419 2009-05-22
41c
<210> 8
<211> 20
<212> DNA
<213> artificial sequence
<220>
<223> PCR primer
<400> 8
taaggtgata gtccagcggg 20
<210> 9
<211> 20
<212> DNA
<213> artificial sequence
<220>
<223> PCR primer
<400> 9
tgtaagtctg tgtgcgagcg 20
<210> 10
<211> 20
<212> DNA
<213> artificial sequence
<220>
<223> PCR primer
<400> 10
gatttagttg cgtgcttgcc 20
<210> 11
<211> 21
<212> DNA
<213> artificial sequence
<220>
<223> PCR primer
<400> 11
cgacggaggc aggagaagca g 21
<210> 12
<211> 21
<212> DNA
<213> artificial sequence
<220>
<223> PCR primer
<400> 12
tgaagtcgcg gtgggcaatg g 21
CA 02670419 2009-05-22
41d
<210> 13
<211> 20
<212> DNA
<213> artificial sequence
<220>
<223> PCR primer
<400> 13
gctgaaagac gatgccactg 20
<210> 14
<211> 20
<212> DNA
<213> artificial sequence
<220>
<223> PCR primer
<400> 14
aggaccccaa aggaccagac 20
